Pharma Stocks

Sun Pharma rallies 6%, top gainer among Sensex stocks; here's why

Sun Pharma to acquire all outstanding shares of Organon for $14.00 per share in an all cash transaction with an enterprise valuation of $11.75 billion.

Cipla gains US FDA nod for Ventolin; analysts see $100 mn sales potential

Cipla has received the US FDA's approval for generic Ventolin inhaler. Analysts see $100-million sales potential from the drug, which could aid US business outlook

Pharma cos brace for soft Q4; US drag persists; domestic growth cushions

Pharma sector may see a 7 per cent Y-o-Y growth in reported sales and a 1 per cent increase in Ebitda, led by steady ex-gRevlimid US sales, healthy domestic growth, and favourable forex movements

Sun Pharma stock falls 5% in strong market: What's worrying investors?

Sun Pharma shares fall 5 per cent amid Organon deal buzz and US tariff concerns. Tech charts show the stock has a 'bearish' outlook

Patent wins vs tariff risks: Analysts picks top pharma stocks to bet on

Pharma stocks have, so far, outperformed the markets in 2026. However, as risk around Trump tariffs resurface, analysts suggest shifting to domestic-focused companies. Here's the investment strategy.

Nifty Pharma index falls for 4th day, sinks 4% as new US tariff risks mount

Nifty Pharma index today: The Trump administration may announce new tariffs on drugmakers that have not struck deals guaranteeing low prices in the country

10 pharma firms launch semaglutide in India; Nomura sees ₹12k-cr mkt

Companies including Dr. Reddy's Laboratories, Sun Pharma, Zydus Lifesciences, Natco Pharma, Alkem Laboratories, and Torrent Pharmaceuticals have developed their own formulations

Nifty Pharma eyes breakout; Biocon, 2 others may rally up to 22%: Analyst

Kunal Shah of Mirae Asset ShareKhan expects breakout on the Nifty Pharma index above 23,500 levels; the analyst recommends Lupin, Biocon and Torrent Pharma as top sectoral stock bets.

Axis Sec sees upside in pharma, hospitals; Lupin, Aurobindo among top bets

Axis Securities has named Lupin, Aurobindo Pharma, Max, and Fortis as top picks, citing strong fundamentals, resilient growth drivers, and robust operational execution

Blue Jet Healthcare tanks 19% in 2 days; nears issue price; here's why

The company said decrease in revenue from operations during Q3FY26 is due to lower sales of PI and Artificial Sweeteners.

Dr Reddy's: 5 technical reasons why Choice Broking is bullish on this stock

Analysts at Choice Broking expects Dr Reddy's Laboratories stock to gain up to 15.5%, and test ₹1,465 levels on the upside in the medium-term given the favourable structure on the weekly chart.

Divi's Labs shares fall 3% on Q3 earnings miss; brokerages split on outlook

Divi's Laboratories reported a consolidated profit after tax (PAT) of ₹583 crore, marginally lower than ₹589 crore in the same period last year

Alembic Pharma shares slide 4% on Q3 profit miss; is it a good time to buy?

Alembic Pharma shares today: Analysts at Motilal Oswal Financial Services (MOFSL) have retained their Neutral rating on Alembic Pharma, with a target price of ₹860 per share

New product launches to keep growth momentum healthy for Sun Pharma

Strong Q3 performance and a steady pipeline of new launches are expected to support Sun Pharma's growth outlook, with brokerages upgrading the stock

Aurobindo Pharma soars 6% on huge volumes; here's what triggered the rally

Aurobindo Pharma stock up on Friday: The government has imposed a Minimum Import Price fixed at ₹2,216/kg for Penicillin G and is expected to provide a significant benefit to the company.

Piramal Pharma shares gain 4% on Q3 results; check key highlights inside

Following the results announcement, the company's share price rose 3.78 per cent to log an intraday high of ₹159.79 per share

Sun Pharma Q3 Preview: Profit, revenue and key factors to watch in Dec qtr

Sun Pharma's net profit is expected to come at ₹3,040 crore, marking a decline of 5.6 per cent Y-o-Y, as against ₹3,220 crore in the year-ago period

Indian CRDMO market to outpace APAC; HDFC Sec starts coverage on top firms

While HDFC Securities has assigned a 'Buy' rating to Divi's Labs, Sai Life Sciences, and Piramal Pharma, it has given an 'Add' rating to Anthem BioSciences and a 'Reduce' rating to Laurus Labs

Gland Pharma rises 5%, hits 1-month high on USFDA nod to eye-allergy drug

Gland Pharma jumped 4.80 per cent to ₹1,790.40, the highest level since December 3, 2025, on the National Stock Exchange.

Indian pharma cos' new drug filings decline to 20-year low, Nomura says

Abbreviated new drug application filings have declined to 600 in the financial year 2025 (ending in September) versus 740 in the preceding year, Nomura said